Literature DB >> 21700865

Human fatty liver disease: old questions and new insights.

Jonathan C Cohen1, Jay D Horton, Helen H Hobbs.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a burgeoning health problem that affects one-third of adults and an increasing number of children in developed countries. The disease begins with the aberrant accumulation of triglyceride in the liver, which in some individuals elicits an inflammatory response that can progress to cirrhosis and liver cancer. Although NAFLD is strongly associated with obesity and insulin resistance, its pathogenesis remains poorly understood, and therapeutic options are limited. Here, we discuss recent mechanistic insights into NAFLD, focusing primarily on those that have emerged from human genetic and metabolic studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700865      PMCID: PMC3229276          DOI: 10.1126/science.1204265

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  50 in total

1.  Increased prevalence of insulin resistance and nonalcoholic fatty liver disease in Asian-Indian men.

Authors:  Kitt Falk Petersen; Sylvie Dufour; Jing Feng; Douglas Befroy; James Dziura; Chiara Dalla Man; Claudio Cobelli; Gerald I Shulman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-11-17       Impact factor: 11.205

Review 2.  Carbohydrate response element binding protein, ChREBP, a transcription factor coupling hepatic glucose utilization and lipid synthesis.

Authors:  Kosaku Uyeda; Joyce J Repa
Journal:  Cell Metab       Date:  2006-08       Impact factor: 27.287

3.  Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds.

Authors:  V M Struben; E E Hespenheide; S H Caldwell
Journal:  Am J Med       Date:  2000-01       Impact factor: 4.965

4.  Proteins under new management: lipid droplets deliver.

Authors:  Michael A Welte
Journal:  Trends Cell Biol       Date:  2007-09-04       Impact factor: 20.808

5.  Citrin deficiency as a cause of chronic liver disorder mimicking non-alcoholic fatty liver disease.

Authors:  Michiharu Komatsu; Masahide Yazaki; Naoki Tanaka; Kenji Sano; Etsuko Hashimoto; Yo-ichi Takei; Yuan-Zong Song; Eiji Tanaka; Kendo Kiyosawa; Takeyori Saheki; Toshifumi Aoyama; Keiko Kobayashi
Journal:  J Hepatol       Date:  2008-06-10       Impact factor: 25.083

6.  Increased de novo lipogenesis and delayed conversion of large VLDL into intermediate density lipoprotein particles contribute to hyperlipidemia in glycogen storage disease type 1a.

Authors:  Robert H J Bandsma; Berthil H Prinsen; Monique de Sain van Der Velden; Jan-Peter Rake; Theo Boer; G Peter A Smit; Dirk-Jan Reijngoud; Folkert Kuipers
Journal:  Pediatr Res       Date:  2008-06       Impact factor: 3.756

Review 7.  Selective versus total insulin resistance: a pathogenic paradox.

Authors:  Michael S Brown; Joseph L Goldstein
Journal:  Cell Metab       Date:  2008-02       Impact factor: 27.287

8.  Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes.

Authors:  Anna Ludovica Fracanzani; Luca Valenti; Elisabetta Bugianesi; Marco Andreoletti; Agostino Colli; Ester Vanni; Cristina Bertelli; Erika Fatta; Daniela Bignamini; Giulio Marchesini; Silvia Fargion
Journal:  Hepatology       Date:  2008-09       Impact factor: 17.425

9.  Population-based genome-wide association studies reveal six loci influencing plasma levels of liver enzymes.

Authors:  Xin Yuan; Dawn Waterworth; John R B Perry; Noha Lim; Kijoung Song; John C Chambers; Weihua Zhang; Peter Vollenweider; Heide Stirnadel; Toby Johnson; Sven Bergmann; Noam D Beckmann; Yun Li; Luigi Ferrucci; David Melzer; Dena Hernandez; Andrew Singleton; James Scott; Paul Elliott; Gerard Waeber; Lon Cardon; Timothy M Frayling; Jaspal S Kooner; Vincent Mooser
Journal:  Am J Hum Genet       Date:  2008-10       Impact factor: 11.025

10.  Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease.

Authors:  Stefano Romeo; Julia Kozlitina; Chao Xing; Alexander Pertsemlidis; David Cox; Len A Pennacchio; Eric Boerwinkle; Jonathan C Cohen; Helen H Hobbs
Journal:  Nat Genet       Date:  2008-09-25       Impact factor: 38.330

View more
  820 in total

1.  Increased expression of zinc finger protein 267 in non-alcoholic fatty liver disease.

Authors:  Bernd Schnabl; Barbara Czech; Daniela Valletta; Thomas S Weiss; Georgi Kirovski; Claus Hellerbrand
Journal:  Int J Clin Exp Pathol       Date:  2011-09-22

2.  A monocarboxylate transporter required for hepatocyte secretion of ketone bodies during fasting.

Authors:  Sarah E Hugo; Lourdes Cruz-Garcia; Santhosh Karanth; Ryan M Anderson; Didier Y R Stainier; Amnon Schlegel
Journal:  Genes Dev       Date:  2012-02-01       Impact factor: 11.361

Review 3.  Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.

Authors:  Donald B Jump; Kelli A Lytle; Christopher M Depner; Sasmita Tripathy
Journal:  Pharmacol Ther       Date:  2017-07-16       Impact factor: 12.310

4.  Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride.

Authors:  Sun-pyo Hong; Tae Soo Noh; Seung-Hwan Moon; Young Seok Cho; Eun Jeong Lee; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Dig Dis Sci       Date:  2013-12-11       Impact factor: 3.199

Review 5.  Role of innate immunity in the development of hepatocellular carcinoma.

Authors:  Rajagopal N Aravalli
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

6.  Aortic carboxypeptidase-like protein, a WNT ligand, exacerbates nonalcoholic steatohepatitis.

Authors:  Toshiaki Teratani; Kengo Tomita; Takahiro Suzuki; Hirotaka Furuhashi; Rie Irie; Makoto Nishikawa; Junji Yamamoto; Toshifumi Hibi; Soichiro Miura; Tohru Minamino; Yuichi Oike; Ryota Hokari; Takanori Kanai
Journal:  J Clin Invest       Date:  2018-03-19       Impact factor: 14.808

7.  A novel role of astrocyte elevated gene-1 (AEG-1) in regulating nonalcoholic steatohepatitis (NASH).

Authors:  Jyoti Srivastava; Chadia L Robertson; Kareem Ebeid; Mikhail Dozmorov; Devaraja Rajasekaran; Rachel Mendoza; Ayesha Siddiq; Maaged A Akiel; Nidhi Jariwala; Xue-Ning Shen; Jolene J Windle; Mark A Subler; Nitai D Mukhopadhyay; Shah Giashuddin; Shobha Ghosh; Zhao Lai; Yidong Chen; Paul B Fisher; Aliasger K Salem; Arun J Sanyal; Devanand Sarkar
Journal:  Hepatology       Date:  2017-06-30       Impact factor: 17.425

8.  Nonalcoholic fatty liver disease induced by noncanonical Wnt and its rescue by Wnt3a.

Authors:  Shuxia Wang; Kangxing Song; Roshni Srivastava; Chao Dong; Gwang-Woong Go; Na Li; Yasuko Iwakiri; Arya Mani
Journal:  FASEB J       Date:  2015-04-27       Impact factor: 5.191

Review 9.  Enzymatic and nonenzymatic protein acetylations control glycolysis process in liver diseases.

Authors:  Juan Li; Tongxin Wang; Jun Xia; Weilei Yao; Feiruo Huang
Journal:  FASEB J       Date:  2019-08-01       Impact factor: 5.191

10.  Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes.

Authors:  Erikka Loftfield; Neal D Freedman; Gabriel Y Lai; Stephanie J Weinstein; Katherine A McGlynn; Philip R Taylor; Satu Männistö; Demetrius Albanes; Rachael Z Stolzenberg-Solomon
Journal:  Cancer Prev Res (Phila)       Date:  2016-08-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.